Dr. Michael E. Schwartz, DO

Dr. Schwartz practices at Methodist Midlothian Medical Center in Midlothian, Texas, part of Methodist Hospitals of Dallas.

Dr. Schwartz's NPI, 1700847514, was assigned on March 31, 2006. Dr. Schwartz graduated from Dr. Kiran C. Patel College of Osteopathic Medicine in 1990. Dr. Schwartz holds California license 20A20063.

Dr. Schwartz's primary practice is Methodist Midlothian Medical Center, at 1201 E Highway 287, Midlothian, TX 76065 in Ellis County. The practice phone is (469) 846-2000.

Dr. Schwartz's primary practice is Methodist Midlothian Medical Center in Midlothian, Texas, part of Methodist Hospitals of Dallas. Dr. Schwartz is also affiliated with Methodist Mansfield Medical Center. The medical group on file is Methodist Medical Group. Dmand AI also links Dr. Schwartz to 1 more hospital, 4 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Schwartz practices, 4 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Schwartz's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Schwartz is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Dr. Schwartz's licenses on file in 3 states: California, Florida and Texas.

Dmand AI lists acid reflux, chronic indigestion, chronic inflammatory bowel disease (IBD), colonoscopy, gastroenteritis, gastrointestinal bleeding, hemorrhoids and irritable bowel syndrome (IBS) among the conditions Dr. Schwartz treats.

CMS data shows 331 Medicare services from Dr. Schwartz across 12 procedure codes in 2024, for 185 Medicare patients. Medicare paid $33,301 for them.

CMS counts 185 Medicare patients who saw Dr. Schwartz in 2024. The largest group is 65 to 74, with 87 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 50% are also on Medicaid. Their average risk score is 2.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Schwartz's median patient age at 64, with 55% women.

In 2024, Dr. Schwartz wrote 580 Medicare Part D claims for 212 patients. 75% of them were for generic drugs. CMS names the drug for 455 of them, across 13 drugs with 11 or more claims each, at $38,144 in total drug cost. In 2023, CMS named 326 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Schwartz for performance year 2024, reported as part of a group. Dr. Schwartz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 52 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Schwartz, more than 64% of the clinicians it reports for that procedure.

Dmand AI links 3 papers to Dr. Schwartz. The most frequent topics are Brain Injuries. Dr. Schwartz's most frequent co-authors are Steven David Abramowitz, MD, Lance L. Goetz, MD and Chester H. Ho, MD.

Dmand AI links Dr. Schwartz to 4 clinical trials, 2 of them phase 2/3 studies. Conditions studied include Constipation, Signs and Symptoms, Digestive and Dyspepsia. Bausch Health Americas, Inc. sponsors the most, 2.

CMS Open Payments shows 81 general payments to Dr. Schwartz from 26 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 93% of the total. Abbvie Inc. paid the most, $619.

Dmand AI lists 2 awards for Dr. Schwartz, most recently CMS Stage 1 2012 in 2011.

Dr. Schwartz graduated from Dr. Kiran C. Patel College of Osteopathic Medicine in 1990. Dr. Schwartz is a member of ACG.

Dr. Schwartz is in network with 21 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.